The emerging role of the microbiome in Alzheimer's disease

Wasén, Caroline; Simonsen, Ella; Ekwudo, Millicent N.; Profant, Martin; Cox, Laura M.

doi:10.1016/bs.irn.2022.09.001

Cited by 14 publications

(3 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, evidence using AD animal models showed positive effects after treatment with antibiotics, probiotics, diet modification, or after fecal microbiota transplantation [63,77]. Thus, modulation of the gut microbiota could be a possible therapeutic and preventive intervention to alleviate symptoms or slow down the progression of AD [78][79][80].…”

Section: Alzheimer's Diseasementioning

confidence: 99%

MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease

Raffaele

Silvestro

Mazzon

2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disorder known to be the leading cause of dementia worldwide. Many microRNAs (miRNAs) were found deregulated in the brain or blood of AD patients, suggesting a possible key role in different stages of neurodegeneration. In particular, mitogen-activated protein kinases (MAPK) signaling can be impaired by miRNA dysregulation during AD. Indeed, the aberrant MAPK pathway may facilitate the development of amyloid-beta (Aβ) and Tau pathology, oxidative stress, neuroinflammation, and brain cell death. The aim of this review was to describe the molecular interactions between miRNAs and MAPKs during AD pathogenesis by selecting evidence from experimental AD models. Publications ranging from 2010 to 2023 were considered, based on PubMed and Web of Science databases. According to obtained data, several miRNA deregulations may regulate MAPK signaling in different stages of AD and conversely. Moreover, overexpressing or silencing miRNAs involved in MAPK regulation was seen to improve cognitive deficits in AD animal models. In particular, miR-132 is of particular interest due to its neuroprotective functions by inhibiting Aβ and Tau depositions, as well as oxidative stress, through ERK/MAPK1 signaling modulation. However, further investigations are required to confirm and implement these promising results.

show abstract

Section: Alzheimer's Diseasementioning

confidence: 99%

MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease

Raffaele

Silvestro

Mazzon

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Similar to the MD, it primarily consists of foods from plant sources, including fruits, vegetables, grains, nuts, and seeds, with limitations on the consumption of animal products, such as meat, dairy, and eggs [106]. This dietary pattern contains essential functional nutrients with antioxidant, anti-inflammatory, and free-radical-fighting characteristics generated by oxidative stress that contribute to intestinal and brain health [107]. In a study that aimed to assess whether the MD could alter the intestinal microbiota, it was observed that the MD altered the intestinal microbiota with a higher Firmicutes/Bacteroidetes ratio and lower inflammatory markers [108].…”

Section: Diet As a Modulator Of Gastrointestinal Microbiomementioning

confidence: 99%

“…However, clinical trials involving these diets should be conducted to assess their effect on delaying the progression of AD or its prodromal phase. [107]. In a study that aimed to assess whether the MD could alter the intestinal microbiota, it was observed that the MD altered the intestinal microbiota with a higher Firmicutes/Bacteroidetes ratio and lower inflammatory markers [108].…”

Section: Diet As a Modulator Of Gastrointestinal Microbiomementioning

confidence: 99%

Lipids, Gut Microbiota, and the Complex Relationship with Alzheimer’s Disease: A Narrative Review

Simão,

Vieira,

Tosatti

et al. 2023

Nutrients

View full text Add to dashboard Cite

Alzheimer’s Disease (AD) is a multifactorial, progressive, and chronic neurodegenerative disorder associated with the aging process. Memory deficits, cognitive impairment, and motor dysfunction are characteristics of AD. It is estimated that, by 2050, 131.5 million people will have AD. There is evidence that the gastrointestinal microbiome and diet may contribute to the development of AD or act preventively. Communication between the brain and the intestine occurs through immune cells in the mucosa and endocrine cells, or via the vagus nerve. Aging promotes intestinal dysbiosis, characterized by an increase in pro-inflammatory pathogenic bacteria and a reduction in anti-inflammatory response-mediating bacteria, thus contributing to neuroinflammation and neuronal damage, ultimately leading to cognitive decline. Therefore, the microbiota–gut–brain axis has a significant impact on neurodegenerative disorders. Lipids may play a preventive or contributory role in the development of AD. High consumption of saturated and trans fats can increase cortisol release and lead to other chronic diseases associated with AD. Conversely, low levels of omega-3 polyunsaturated fatty acids may be linked to neurodegenerative diseases. Unlike other studies, this review aims to describe, in an integrative way, the interaction between the gastrointestinal microbiome, lipids, and AD, providing valuable insights into how the relationship between these factors affects disease progression, contributing to prevention and treatment strategies.

show abstract